Abstracts tagged "quality of life"

Abstract Number: 0640 • ACR Convergence 2025
Impact of Clinically Important Improvements in Patient-Reported Outcomes on Disease Activity in Patients With Systemic Lupus Erythematosus Treated With Upadacitinib or Placebo: Results From the Phase 2 SLEek Study
Vibeke Strand¹, Zahi Touma², Anca Askanase³, Christopher Saffore⁴, Denise Kruzikas⁵, Karim Masri⁵, Siran Fang⁵, Yi Peng⁶, Patti Katz⁷ and Marta Mosca⁸, ¹Stanford University School of Medicine, Palo Alto CA, Portola Valley, CA, ²University of Toronto, Toronto, ON, Canada, ³Columbia University Medical Center, New York, NY, ⁴AbbVie Inc., waukegan, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Inc., Maple Grove, MN, ⁷UCSF, San Rafael, CA, ⁸University of Pisa, Pisa, Pisa, Italy
Background/Purpose: This analysis evaluated associations between clinically important improvements in patient-reported outcomes (PROs) and reduced disease activity from the phase 2 SLEek trial evaluating upadacitinib…
Abstract Number: 2441 • ACR Convergence 2025
Dapirolizumab Pegol Demonstrated Improvement in Quality of Life of Patients with Systemic Lupus Erythematosus: LupusQoL Results from a Phase 3 Trial
Zahi Touma¹, Cynthia Aranow², Ioannis Parodis³, Rosalind Ramsey-Goldman⁴, Matthias Schneider⁵, Christine de La Loge⁶, Teri Jimenez⁷, Mina Nejati⁸ and Laurent arnaud⁹, ¹University of Toronto, Toronto, ON, Canada, ²Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ³Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Clinic of Rheumatology and Hiller Research Unit, Heinrich-Heine-University, Düsseldorf, Germany, ⁶UCB, Brussels, Belgium, ⁷UCB, Raleigh, NC, ⁸Biogen, Cambridge, MA, ⁹Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, INSERM UMR-S ¹¹⁰⁹, Strasbourg, France, Strasbourg, France
Background/Purpose: SLE imposes significant disease burden and diminishes health-related quality of life (HRQoL); improvement of HRQoL is therefore a key treatment goal in SLE.1,2 Dapirolizumab…
Abstract Number: 1635 • ACR Convergence 2025
Association Between Treatment Adherence and Frailty in Patients with Rheumatic Diseases
Daniela L. Guillen-Tejada¹, Aura Matilde Jiménez-Garduño¹ and Montserrat Lamuño Encorrada², ¹Universidad de las Américas Puebla, Puebla, Mexico, ²Hospital Ángeles Puebla, Puebla, Mexico
Background/Purpose: Management of rheumatic diseases relies on chronic treatment, often with a greater risk of nonadherence. Frailty is characterized by decreased physiological function that increases patients’…
Abstract Number: 1262 • ACR Convergence 2025
Perspectives of Lupus Patients on Quality of Life Measures: A Qualitative Study
Cristina Arriens¹, Fredonna Carthen², Alexandre Cammarata-Mouchtouris¹, Judith James¹, Joan Merrill³ and Motolani Ogunsanya⁴, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma, OK, ³Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ⁴University of Oklahoma Health Sciences Center, Edmond, OK
Background/Purpose: Lupus has profound impact on physical, social, and emotional well-being. Health-related quality of life (HRQOL) measures are increasingly incorporated into lupus research and the…
Abstract Number: 0634 • ACR Convergence 2025
Association of Lifestyle and Integrative Health Practices with Health-Related Quality of Life in Women with Systemic Lupus Erythematosus and Connective Tissue Disease
Sarah Lieber¹, Yongjay Kim², Lucy Masto³, Amaya Smole⁴, Neha Nagpal¹, Ranqing Lan¹, Michael Parides¹, Caroline Siegel¹, Lisa Mandl¹, Michael Lockshin⁵, Medha Barbhaiya¹ and Lisa Sammaritano¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Englewood Cliffs, NJ, ³Hospital for Special Surgery, San Francisco, CA, ⁴Hospital for Special Surgery, Brooklyn, NY, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Although available evidence supports the benefits of lifestyle interventions in SLE, the prevalence of lifestyle and integrative health behaviors and their association with health-related…
Abstract Number: 2429 • ACR Convergence 2025
mHealth-enabled Peer Coaching for Fatigue in Systemic Lupus Erythematosus (SLE): Preliminary Results from the Restore Energy, Activity Can Help (REACH) Pilot Randomized Controlled Trial
Shanthini Kasturi¹, Erin Morrissey¹, Anna Deck², Nina Gulati², Zoe Gilbard², Kiran Singh¹, Monique Gore-Massy³, Faye Chiu⁴, Priscilla Calvache⁵, Jillian Rose-Smith⁵, Andre Ogura⁶, Lucas Ogura Dantas⁶, Wambui Machua⁷, Julia Nguyen⁸, Lisa Mandl⁵, Hocine Tighiouart¹, Ludovic Trinquart², Iris Navarro-Millan⁹ and Sara Folta¹⁰, ¹Tufts Medical Center, Boston, MA, ²Tufts University School of Medicine, Boston, MA, ³N/A, West Orange, NJ, ⁴N/A, New York, NY, ⁵Hospital for Special Surgery, New York, NY, ⁶Ambulomics, Arlington, MA, ⁷Piedmont Healthcare, Atlanta, GA, ⁸Hospital for Special Surgery, New York, ⁹Weill Cornell Medicine, Hospital for Special Surgery, Poughkeepsie, NY, ¹⁰Tufts Friedman School of Nutrition, Boston, MA
Background/Purpose: Fatigue is a highly prevalent and debilitating symptom affecting up to 90% of individuals living with systemic lupus erythematosus (SLE). Despite its significant impact,…
Abstract Number: 1573 • ACR Convergence 2025
Health-related quality of life over 15 years in systemic sclerosis: impact of sex and survival
Katherine van der Wouden¹, Georgy Gomon², Rachel Knevel², Michel Tsang-A-Sjoe³, Alexandre Voskuijl³ and Jeska de Vries-Bouwstra², ¹Leiden University Medical Center and Amsterdam University Medical Center, Leiden, Zuid-Holland, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Amsterdam University Medical Center, Amsterdam, Netherlands
Background/Purpose: Patients with systemic sclerosis (SSc) face an uncertain long‑term outlook; understanding how their health‑related quality of life (HRQoL) changes over time can help them…
Abstract Number: 1261 • ACR Convergence 2025
Use of telemedicine to address ‘off target’ symptoms in psoriatic arthritis (PsA): implementation of PsOWell™ in PsA
Carter Pason¹, Sarah Hopkins Gillespie¹, Joelle Koplin², Rachael Hewitt³, Christine Bundy³, Ethan Craig⁴, Laura Coates⁵, Jessica A. Walsh⁶ and Alexis Ogdie⁷, ¹University of Pennsylvania, Philadelphia, PA, ²Penn Medicine, Philadelphia, PA, ³University of Cardiff, Cardiff, United Kingdom, ⁴University of Pennsylvania, Wallingford, PA, ⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁶Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁷Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE
Background/Purpose: Approximately 60-70% of patients with PsA do not reach minimal disease activity (MDA) on therapy. However, in many cases, this may not be related…
Abstract Number: 0573 • ACR Convergence 2025
Effects of Sonelokimab, an IL-17A- and IL-17F-Inhibiting Nanobody, on Patient-Reported Symptoms and Quality of Life in Psoriatic Arthritis: Results From the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial
Joseph F Merola¹, Alexis Ogdie², Alice B. Gottlieb³, Fabian Proft⁴, Nuala Brennan⁵, Alex Godwood⁵, Matthew R. Thomas⁵, Eva Cullen⁵, Kristian Reich⁶, Laura Coates⁷ and Laure Gossec⁸, ¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, ⁴Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵MoonLake Immunotherapeutics AG, Zug, Switzerland, ⁶MoonLake Immunotherapeutics AG and Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Zug, Switzerland, ⁷Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁸Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: Sonelokimab (SLK) is a novel IL-17A- and IL-17F-inhibiting Nanobody designed to target difficult-to-reach sites of inflammation due to its small size and albumin-binding domain.…
Abstract Number: 2384 • ACR Convergence 2025
Patient-Reported Quality of Life in SLE: Association with Biomarker-Derived Disease Activity Index (L-DAI) and hSLEDAI in a Prospective Cohort
Bernard Rubin¹, Rou Sore¹, Melissa Munroe¹, Daniele DeFreese¹, Adrian Holloway¹, Mohan Purushothaman¹, Yangfen Li², Hu Zeng², Uma Thanarajasingam², Judith James³ and Eldon Jupe¹, ¹Progentec Diagnostics, Inc., Oklahoma City, OK, ²Mayo Clinic, Rochester, MN, ³Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systematic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by unpredictable disease activity. The Lupus Disease Activity Index (L-DAI) is a blood-based assessment…
Abstract Number: 1551 • ACR Convergence 2025
Disease Burden and Treatment Preferences for Systemic Lupus Erythematosus: Results from a Global Real-World Survey
Zahi Touma¹, Christopher Saffore², Karim Masri³, Jerry Clewell³, Emily Goddard⁴, Grace O'Neill⁴, Madelane Foxall⁴ and Karen H. Costenbader⁵, ¹University of Toronto, Toronto, ON, Canada, ²AbbVie Inc., waukegan, IL, ³AbbVie Inc., North Chicago, IL, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: As new treatment options for systemic lupus erythematosus (SLE) become available, understanding patient burden and preferences is key to optimizing shared decision-making. This study…
Abstract Number: 1259 • ACR Convergence 2025
Patient and Caregiver Perspectives on the Burden of Disease in Uncontrolled Gout: A Cross-Sectional Survey Study
Angelo Gaffo¹, Bhavisha Desai², Abiola Oladapo³, Nana Kragh⁴, Rebekah Zincavage⁵, Brad Padilla⁵ and Naomi Schlesinger⁶, ¹Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ²Sobi, Glastonbury, CT, ³Sobi INC, Waltham, MA, ⁴Sobi, Kongens Lyngby, Denmark, ⁵Stratevi, Boston, ⁶Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA, Salt Lake City, UT
Background/Purpose: Many patients with uncontrolled gout (UG) experience symptoms despite being on urate-lowering therapy (ULT), often requiring support from informal caregivers. UG impacts patients and…
Abstract Number: 0794 • ACR Convergence 2025
Using Artificial Intelligence to Analyze Multilingual Qualitative Data in Lupus Pregnancy Research: A Proof of Concept with Large Language Models
Romina Boers¹, Grace Terry² and Bella Mehta³, ¹Weil Cornell Medicine, New York, ²Weil Cornell Medicine, Ne wYork, ³Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ
Background/Purpose: Women with systemic lupus erythematosus (SLE), particularly those of childbearing age, face heightened risks during pregnancy, including disease flares, adverse maternal-fetal outcomes, and emotional…
Abstract Number: 2341 • ACR Convergence 2025
Bimekizumab Treatment Resulted in Long-Term Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire in Patients with Active Psoriatic Arthritis: Up to 3-Year Results from Two Phase 3 Studies
Ana-Maria Orbai¹, Dafna D. Gladman², Laura Coates³, Maarten de Wit⁴, Barbara Ink⁵, Rajan Bajracharya⁵, Patrick Healy⁶, Jérémy Lambert⁷ and Laure Gossec⁸, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁴Patient Research Partner, Stichting Tools, Amsterdam, Netherlands, ⁵UCB, Slough, England, United Kingdom, ⁶UCB, Morrisville, NC, ⁷UCB, Colombes, France, ⁸Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. The PsA Impact of Disease-12 (PsAID-12) questionnaire is…
Abstract Number: 1503 • ACR Convergence 2025
Lupus Disease Activity Adversely Affects the Quality of Life but not Intimate Relationship and Sexual Function in Indian Female Lupus Patients
Ranjan Gupta, Nilanchali Singh, Nisha Jawaliya, Rudra Prosad Goswami, Soniya Dhiman and Parul baisoya, All India Institute of Medical Sciences, New Delhi, Delhi, India
Background/Purpose: Systemic Lupus Erythematosus (SLE) disease activity can affect the normal functioning of the patients. This functioning in various domains can be assessed using quality…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].